Associations - Irene (pyrotinib)

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pyrotinib Sensitive: B - Late Trials pyrotinib Sensitive : B	pyrotinib Sensitive: B - Late Trials pyrotinib Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pyrotinib Sensitive: B - Late Trials trastuzumab + pyrotinib Sensitive : B	trastuzumab + pyrotinib Sensitive: B - Late Trials trastuzumab + pyrotinib Sensitive : B
HER-2 amplification	Non Small Cell Lung Cancer	HER-2 amplification	Non Small Cell Lung Cancer	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2
HER-2 positive	Lung Cancer	HER-2 positive	Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 mutation	Gastric Cancer	HER-2 mutation	Gastric Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 mutation	Lung Cancer	HER-2 mutation	Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 positive	Solid Tumor	HER-2 positive	Solid Tumor	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2	rivoceranib + pyrotinib Sensitive: C2 – Inclusion Criteria rivoceranib + pyrotinib Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 amplification	Non Small Cell Lung Cancer	HER-2 amplification	Non Small Cell Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 positive	Non Small Cell Lung Cancer	HER-2 positive	Non Small Cell Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 exon 20 mutation	Non Small Cell Lung Cancer	HER-2 exon 20 mutation	Non Small Cell Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pyrotinib + inetetamab Sensitive: C2 – Inclusion Criteria pyrotinib + inetetamab Sensitive : C2	pyrotinib + inetetamab Sensitive: C2 – Inclusion Criteria pyrotinib + inetetamab Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	camrelizumab + pyrotinib Sensitive: C2 – Inclusion Criteria camrelizumab + pyrotinib Sensitive : C2	camrelizumab + pyrotinib Sensitive: C2 – Inclusion Criteria camrelizumab + pyrotinib Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	camrelizumab + pyrotinib Sensitive: C2 – Inclusion Criteria camrelizumab + pyrotinib Sensitive : C2	camrelizumab + pyrotinib Sensitive: C2 – Inclusion Criteria camrelizumab + pyrotinib Sensitive : C2
HER-2 positive	Solid Tumor	HER-2 positive	Solid Tumor	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	pyrotinib + inetetamab Sensitive: C2 – Inclusion Criteria pyrotinib + inetetamab Sensitive : C2	pyrotinib + inetetamab Sensitive: C2 – Inclusion Criteria pyrotinib + inetetamab Sensitive : C2
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2
HER-2 G766V	Non Small Cell Lung Cancer	HER-2 G766V	Non Small Cell Lung Cancer	lapatinib + pyrotinib Sensitive: C3 – Early Trials lapatinib + pyrotinib Sensitive : C3	lapatinib + pyrotinib Sensitive: C3 – Early Trials lapatinib + pyrotinib Sensitive : C3
HER-2 A775_G776insYVMA	Non Small Cell Lung Cancer	HER-2 A775_G776insYVMA	Non Small Cell Lung Cancer	rivoceranib + pyrotinib Sensitive: C3 – Early Trials rivoceranib + pyrotinib Sensitive : C3	rivoceranib + pyrotinib Sensitive: C3 – Early Trials rivoceranib + pyrotinib Sensitive : C3
HER-2 positive	Thymic Carcinoma	HER-2 positive	Thymic Carcinoma	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3
HER-2 mutation	Thymic Carcinoma	HER-2 mutation	Thymic Carcinoma	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3
HER-2 mutation	Colorectal Cancer	HER-2 mutation	Colorectal Cancer	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3
HER-2 amplification	Biliary Tract Cancer	HER-2 amplification	Biliary Tract Cancer	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3

Irene (pyrotinib)

Associations
(79)

Associations
(79)

Irene (pyrotinib)

Associations(79)

Associations(79)

Associations
(79)

Associations
(79)